Navigation Links
Sorafenib significantly improves the length of time before breast cancer worsens
Date:9/23/2009

Berlin, Germany: One of the first of a series of trials to investigate the use of sorafenib a targeted anti-cancer drug for the treatment of advanced breast cancer has found that if it is combined with the chemotherapy drug, capecitabine, it makes a significant difference to the time women live without their disease worsening.

Principal investigator of the study, Professor Jos Baselga told Europe's largest cancer congress, ECCO 15 ESMO 34 [1], in Berlin today (Wednesday 23 September): "This is the first, large, randomised study that demonstrates significant clinical activity of sorafenib in breast cancer when given in combination with chemotherapy. Our results showed that patients who received sorafenib plus capecitabine had a 74% percent improvement in the time they lived without their disease worsening compared to those who received the chemotherapy alone. This is a very positive study and the magnitude of the benefit is such that it suggests that this agent will be an important addition to our therapeutic armoury in breast cancer."

Sorafenib (Nexavar) is a potent multi-kinase inhibitor, which works by interfering with the growth of cancer cells and slowing the growth of new blood vessels within the tumour. Until now, it has only been used in the treatment of kidney and liver cancer.

Prof Baselga, who is head of the oncology department at Vall d'Hebron University Hospital (Barcelona, Spain), president of ESMO (European Society for Medical Oncology) and a member of the ECCO (European CanCer Organisation) executive committee, and his colleagues in Spain, France and Brazil enrolled 229 patients with locally advanced or metastatic breast cancer in the double-blind, randomised phase II clinical trial between June 2007 and December 2008. They randomised the patients to receive capecitabine (1000 mg/m2 pill taken twice daily for 14 of every 21 days) and a placebo (114 women), or capecitabine and sorafenib (400 mg pill taken twice daily
'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-771-129-6986
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Drug Sorafenib Improves Kidney Cancer Outcomes
2. Sorafenib Shows Promise for Heart-Lung Disease
3. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
4. Sorafenib Slows Growth of Some Leukemias
5. Women with atrial fibrillation are at significantly higher risk of stroke and death compared to men
6. Phoenix Children's Hospital Significantly Reduces Costs with Orion Health™ Technology
7. Radiologists find a technique to significantly reduce patient radiation dose during CT angiography
8. New Survey of People With Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated
9. African Americans at Significantly Higher Risk of DVT or Blood Clots
10. Significantly Higher Percentage of Hetastarch Recipients Underwent a Surgical Procedure Than Those Receiving Albumin/Plasma Protein Fraction
11. New Data Show ChloraPrep(R) Significantly More Effective Than DuraPrep(TM) and Povidone-Iodine in Eliminating Bacteria From Skin Prior to Shoulder Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014 Splashtop, Inc. announced ... Program . Splashtop Business and Splashtop Enterprise will now ... will leverage the MaaS360 WorkPlace SDK to enable enterprise-grade ... Business and Splashtop Enterprise offer secure remote access, support, ... High performance, ease of use, collaborative features, and ...
(Date:7/25/2014)... 2014 Training Mask LLC, is proud ... an endorsement agreement to promote the mask and its’ ... for over 10 years, and ran over 30 ultra ... of the Angeles Crest 100-mile endurance run. Brian is ... of the endurance, strength and conditioning paradigm. He created ...
(Date:7/25/2014)... An alpha olefin is an olefin or an ... alpha position of the carbon chain, or between the 1st ... namely, branched and linear (or normal). The alpha olefin market ... its applications such as polyethylene co-monomers and synthetic lubricants, across ... Europe have been lucrative markets for alpha olefins; however, Asia-Pacific ...
(Date:7/25/2014)... -- The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... Patent Pool (MPP) and Gilead Sciences, Inc. to ... promising new HIV medication. The agreement was announced ... in Melbourne, Australia. , While TAF is ... suggests it could be a key ingredient in ...
(Date:7/25/2014)... 2014 Ross A. Clevens, MD, FACS, ... to join the exclusive Obagi Clinical Advisory Board, comprised ... surgeons, plastic surgeons and dermatologists. , Dr. Clevens ... Board of thought leaders held its first meeting in ... to give Obagi the opportunity to meet with eight ...
Breaking Medicine News(10 mins):Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 2Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 3Health News:Splashtop Joins the MaaS360 WorkPlace Partner Program 4Health News:Training Mask LLC Announces the Signing of World-Renowned Coach Brian MacKenzie 2Health News:Training Mask LLC Announces the Signing of World-Renowned Coach Brian MacKenzie 3Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Alpha Olefins Market is Expected to Reach $1,958 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Renowned Melbourne Plastic Surgeon to Join Private Medical Advisory Board 2
... Fitzpatrick, PhD, RN, Executive Vice President and Healthcare Practice ... winning poster Optimizing Nursing Human Capital: The Five Rights ... (AONE) 42nd Annual Meeting and Exposition, held April 15 ... in San Antonio Texas. The AONE Annual Meeting and ...
... N.J.¿ April 8 ORTHOCON¿ Inc. today announced that ... President and Chief Executive Officer. The company also announced ... led by top-tier healthcare investors. ORTHOCON is developing ... Company,s versatile technology platform may be leveraged to deliver ...
... Solutions and Logicalis Initiate Collaborative Sales Agreements ... Access to Federal Healthcare IT Stimulus FundsCHICAGO, ... interoperability of disparate healthcare IT systems, announced ... Software Information Systems (SIS) and Micro Solutions. ...
... to its line of Workmaster® Storage Cabinets (WSC). , ... ... adds 7 new pedestal configurations to its line of ... large capacity drawers in combination with split-door cabinet compartments. The cabinet ...
... received full accreditation from URAC as a health call center. By ... all relevant standards and performs nurse line and other health information ... appropriate care and treatment advice. , ... South Portland, ...
... Seguro Popular, a Mexican health care program instituted in ... poorer households, according to an evaluation conducted by researchers ... , The study was designed and led by ... of the Institute for Quantitative Social Science at Harvard. ...
Cached Medicine News:Health News:Dr. Therese Fitzpatrick to Present Award Winning Poster at AONE 2Health News:ORTHOCON Announces Appointment of New CEO and $25 Million Series B Financing 2Health News:Compressus Launches Partnerships With Two Avnet HealthPath(TM) Partners to Accelerate Access to Interoperability Solutions 2Health News:Compressus Launches Partnerships With Two Avnet HealthPath(TM) Partners to Accelerate Access to Interoperability Solutions 3Health News:Compressus Launches Partnerships With Two Avnet HealthPath(TM) Partners to Accelerate Access to Interoperability Solutions 4Health News:Even MORE Storage for IAC Industries' Workmaster™ Storage Cabinet Workbenches 2Health News:Even MORE Storage for IAC Industries' Workmaster™ Storage Cabinet Workbenches 3Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 2Health News:SironaHealth Receives URAC Accreditation as a Health Call Center 3Health News:New Mexican health-care program successful at reducing crippling health care costs 2Health News:New Mexican health-care program successful at reducing crippling health care costs 3
(Date:7/24/2014)... July 24, 2014  Kinex Pharmaceuticals announced the receipt ... Company,s KX2-391 Ointment for the commencement of a Phase ... Company,s third IND to be allowed by the US ... is a synthetic, orally active and highly selective inhibitor ... promotes the induction of p53, G2/M arrest of proliferating ...
(Date:7/24/2014)...  The American Association for Homecare (AAHomecare) yesterday ... help address audit issues in the HME industry ... the information technology lead in shaping its HME ... billing and business management solutions for nearly 3,000 ... support this important initiative on behalf of all ...
(Date:7/24/2014)... Research and Markets  has announced the ... Product, Component, Application and Geography - Global Forecast to ... http://photos.prnewswire.com/prnh/20130307/600769 ... a moderate growth as the markets of the U.S. ... the saturation levels. The demand is expected to come ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2
... Mettler-Toledo International Inc. (NYSE: MTD ) today ... Life Sciences Conference in New York on Wednesday, September 22, ... webcast of the presentation, visit the investor relations page on ... of the webcast will be available for seven days. ...
... HeartWare International, Inc. (Nasdaq: HTWR ; ... circulatory support technologies that are revolutionizing the treatment of ... is scheduled to make an investor presentation at the ... 21, at 12:30 pm EDT.  The conference will be ...
Cached Medicine Technology:HeartWare to Present at the UBS 2010 Global Life Sciences Conference 2
... RayShield X-Drape combines full 0.25 ... Soft Fiber sterile drape material that ... sterile field between the clinician and ... when the clinician must be in ...
... The first mobile clinical assistant that ... convergence of technologies in the C5 ... normally do during your,shift such as ... take pictures using one single device.,With ...
Patent Pending lateral flow assay platform that contributes to increased sensitivty...
Colloidal Gold Conjugated, Rabbit anti-goat IgG (H&L) - 50 OD...
Medicine Products: